02008nas a2200277   4500000000100000008004100001260004400042653001200086653001500098653002000113653002500133653001100158100001500169700001500184700001500199700001600214700001000230700001100240700001000251700001300261700001600274700001400290245006300304520134900367022001401716       2023                            d  bSpringer Science and Business Media LLC10aSurgery10aLymphedema10aQuality of Life10aLymphatic filariasis10aCancer1 aJaszkul KM1 aFarrokhi K1 aCastanov V1 aMinkhorst K1 aLi EA1 aSano L1 aKim S1 aKeelan S1 aAl-Ghanim K1 aSimpson A00aGlobal impact of lymphedema on quality of life and society3 a<p>Lymphedema is a chronic disorder of the lymphatic system characterized by the accumulation of interstitial fluid in tissues. It affects millions of individuals worldwide, resulting in significant disability and morbidity. Despite its prevalence, it is often an underappreciated clinical entity. In this narrative review, we critically examined and synthesized currently available peer-reviewed literature on the global epidemiology, pathophysiology, and societal burden of lymphedema. Most patients have a secondary cause of lymphedema, such as lymphatic filariasis, mostly prevalent in Asia, South America, and Africa. A smaller proportion of lymphedema is secondary to malignancy or post-oncological treatment. Breast cancer, prostate cancer, cervical cancer, and melanoma are most often associated with causing lymphedema secondary to nodal involvement. Several tools have been developed to assess the effect of lymphedema on quality of life which can cause personal and financial impacts on those affected. Lymphedema is a globally prevalent but underappreciated disease in the developed and developing world. Lymphedema causes a significant burden on quality of life and financial stability to patients. Therefore, awareness among the healthcare team and patient education on prevention and minimizing morbidity are crucial.&nbsp;</p>
  a1435-0130